Navigation Links
Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to Global Central Lab Services
Date:6/21/2013

TOKYO, June 21, 2013 /PRNewswire/ -- Mitsubishi Chemical Medience Corporation (MCM) today announced that the company has signed a Master Service Agreement with the clinical trials division of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH).  The agreement builds on the strengths and capabilities of both companies, and allows LabCorp Clinical Trials and MCM to extend their service offerings to clients in Japan and around the world, respectfully.

"Pharmaceutical sponsors everywhere continue to look to new markets and technologies for drug development opportunities, and our clients are no different," said Mr. Shinichi Yoshihara, President and CEO of Mitsubishi Chemical Medience Corporation.  "We are therefore excited to work closely with LabCorp as a global leader in central lab, biomarker and specialty testing, and with cutting-edge technologies from both sides we are confident this partnership will provide new channels of growth and competitive advantage for both companies."

"MCM is a leading diagnostic laboratory and central lab in Japan with considerable experience and long-standing relationships in the medical and pharmaceutical communities," said Dr. Mark Brecher, LabCorp's Chief Medical Officer.  "The two companies complement each other in this respect, and we look forward to working together to offer a complete global solution for our customers conducting trials in Japan and around the globe."

Both companies will exhibit at the Drug Information Association (DIA) annual meeting taking place June 23-27 in Boston, Mass.  Clients who are interested in learning more about this announcement can visit LabCorp Clinical Trials at booth 1451 or MCM at booth 1548.

About Mitsubishi Chemical Medience Corporation
Mitsubishi Chemical Medience Corporation is a member of the Mitsubishi Chemical Holdings Corporation Group, which is headquartered in Tokyo, Japan. Mitsubishi Chemical Medience is the first company in Japan to establish a business style that combines clinical and diagnostic laboratory testing services with in vitro diagnostics (IVD) and pharmaceutical development support. One of Mitsubishi Chemical Medience's primary business areas is their IVD business, which includes the development, sale, export, and import of in vitro diagnostic reagents and instruments. Mitsubishi Chemical Medience's globally accepted PATHFAST system, a rapid point-of-care immunochemistry analyzer, has been exported to more than 40 countries. Throughout almost five decades of IVD business, customers in various chemical and diagnostic industry segments have come to trust and rely on Mitsubishi Chemical Medience's competence and strength, as represented by the superior quality of their products and customized solutions. To learn more, visit the company's website at http://www.medience.co.jp/english/index.html.


'/>"/>
SOURCE Mitsubishi Chemical Medience Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
2. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
3. ChemAxon Announces New Version of chemicalize.org for Tablet PCs
4. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
5. DOW Chemical at the World Drug Delivery & Formulation Summit 2013
6. Top Insight On Green Chemistry, API Manufacturing, Specialty Chemicals And Supply Chain Management At InformEx USA
7. InformEx Platforms Top Chemical Suppliers In The Specialty, Industrial & Pharmaceutical Ingredients Markets
8. US Animal Health Chemicals Market
9. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
10. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
11. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):